• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail

Search Publications



Starting Date

Ending Date

Order by

Entry Details

Clin Vaccine Immunol 2010 May;17(5):793-801

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL


Novel immunization strategies are needed to enhance the global control of tuberculosis. In this study, we assessed the immunizing activity of a recombinant Modified Vaccinia Ankara construct (MVA/IL-15/5Mtb) which over-expresses five M. tuberculosis antigens (Antigen 85A, Antigen 85B, ESAT6, HSP60, and Mtb39) as well as the molecular adjuvant IL-15. Homologous prime/boost studies showed that the MVA/IL-15/5Mtb vaccine induced moderate but highly persistent protective immune responses for at least 16 months after the initial vaccination and that the interval between the prime and boost did not significantly alter vaccine-induced anti-tuberculosis protective immunity. At 16 months, when the BCG and MVA/IL-15/5Mtb vaccine-induced protection was essentially equivalent, the protective responses after a tuberculous challenge were associated with elevated levels of IFN-gamma, IL17F, Cxcl9, and Cxcl10. To amplify the immunizing potential of the MVA/IL-15/5Mtb vaccine, a heterologous prime/boost regimen was tested using an ESAT6-Antigen 85B (E6-85) fusion protein formulated in DDA/MPL adjuvant as the priming vaccine and the MVA/IL-15/5Mtb recombinant virus as the boosting agent. When the MVA/IL-15/5Mtb vaccine boosting was done at 2 or 6 months following the final fusion protein injections, the prime/boost regimen evoked protective responses against an aerogenic M. tuberculosis challenge which was equivalent to that induced by BCG immunization. Long-term memory after immunization with the E6-85-MVA/IL-15/5Mtb combination regimen was associated with the induction of monofunctional CD4 and CD8 IFN-gamma producing T cells and multifunctional CD4 and CD8 T cells expressing IFN-gamma/TNF-alpha, TNF-alpha/IL2, and IFN-gamma/TNF-alpha/IL2. In contrast, BCG-induced protection was characterized by fewer CD4 and CD8 monofunctional T cells expressing IFN-gamma and only IFN-gamma/TNF-alpha and IFN-gamma/TNF-alpha/IL2 expressing multifunctional T (MFT) cells. Taken together, these results suggest that a heterologous prime/boost protocol using MVA-based tuberculosis vaccines to boost after priming with TB protein/adjuvant preparations should be considered when designing long-lived TB immunization strategies.

Category: Journal Article
PubMed ID: #20357059 DOI: 10.1128/CVI.00006-10
Includes FDA Authors from Scientific Area(s): Biologics
Entry Created: 2011-10-04 Entry Last Modified: 2012-08-29